Study guide
9.5 Drug Product Selection, Generic Substitution & DAW Codes
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
9.5 Drug Product Selection, Generic Substitution & DAW Codes
Key Takeaways Explain This Topic AI
Under the Hatch-Waxman Act of 1984 (FD&C Act § 505(j)), FDA approves therapeutically equivalent generics through Abbreviated New Drug Applications (ANDAs), enabling pharmacists to substitute AB-rated products for the prescribed brand.
FDA's Orange Book assigns A-codes (AA, AB, AN, AO, AP, AT) to therapeutically equivalent products that may be substituted and B-codes (BC, BD, BX, and others) to products that are not therapeutically equivalent and must not be substituted without prescriber authorization.
DAW Code 1 means 'Substitution Not Allowed by Prescriber' and requires dispensing the brand as written; DAW Code 0 means no product-selection instruction was given and the pharmacist follows state substitution law.
Generic substitution is governed by state law—most states permit substitution of an AB-rated generic unless the prescriber writes 'dispense as written' or the patient requests the brand; a few states mandate generic substitution when a therapeutically equivalent product exists.
Therapeutic substitution (switching to a different active ingredient within a drug class) is not routine generic substitution and requires prescriber authorization or a collaborative practice agreement.
Last updated: July 2026
9.5 Drug Product Selection, Generic Substitution & DAW Codes
MPJE Core Concept: "Product selection" is the pharmacist's decision to dispense a generic (therapeutically equivalent) drug in place of the brand-name product the prescriber wrote. The federal framework (Hatch-Waxman Act, FD&C Act § 505, FDA Orange Book) defines which products are substitutable; state law defines when the pharmacist may or must substitute. The MPJE tests both layers and the DAW claim codes that document the choice.
1. The Federal Framework: Hatch-Waxman & ANDA Approvals
The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act ) created the modern generic-drug pathway. A manufacturer may obtain FDA approval of a generic copy of a brand Reference Listed Drug (RLD) through an Abbreviated New Drug Application (ANDA) under FD&C Act § 505(j) . To approve an ANDA, FDA must find the generic is pharmaceutically equivalent (same active ingredient, dosage form, strength, route of administration) and bioequivalent to the RLD. A drug that is both pharmaceutically equivalent and bioequivalent is therapeutically equivalent —FDA's determination that it can be expected to have the same clinical effect and safety profile.
Only therapeutically equivalent products may be routinely substituted for one another without prescriber authorization.
2. The FDA Orange Book: Therapeutic Equivalence Codes
FDA publishes therapeutic-equivalence evaluations in "Approved Drug Products with Therapeutic Equivalence Evaluations" (the Orange Book ). Each multisource product receives a two- or three-letter code; the first letter is decisive.
First Letter Meaning Substitution Permitted?
A FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products Yes (if state law allows)
B FDA does NOT consider the product therapeutically equivalent No
Common A-codes (substitutable): AA, AB, AN, AO, AP, AT . AB is the most common code for solid oral generics and means any bioequivalence concern has been resolved with evidence.
Common B-codes (do not substitute): BC, BD, BE, BN, BP, BR, BS, BT, BX . A B-rated product has a known or potential bioequivalence problem; the pharmacist must dispense the product as prescribed unless the prescriber explicitly authorizes the switch.
Exam trap: Two products can be pharmaceutically equivalent (same active ingredient, strength, dosage form) yet not therapeutically equivalent if one is B-rated—for example, a different dosage form or a formulation with unresolved bioequivalence. Substituting across an A↔B boundary is illegal substitution.
3. State Law: When May or Must the Pharmacist Substitute?
The federal Orange Book answers whether these products can be interchanged safely ; state law answers whether the pharmacist may or must do so. Most state practice acts provide:
Permissive substitution: The pharmacist may substitute an AB-rated generic unless the prescriber writes "dispense as written" / "DAW" / "brand medically necessary," or the patient requests the brand and pays any price difference.
Mandatory substitution: Some states require dispensing the lowest-cost therapeutically equivalent generic unless a DAW exception is documented (common under Medicaid formularies).
Restricted substitution for narrow-therapeutic-index (NTI) drugs: For drugs such as warfarin, levothyroxine, phenytoin, carbamazepine, theophylline, and valproate, some states restrict substitution or require explicit consent and monitoring even though the Orange Book may code the products AB. State law is the limiting rule.
Documentation: Most states require the pharmacist to record the substitution, the NDC of the product actually dispensed, and—where applicable—pass any savings to the patient or third-party payer.
Therapeutic substitution (switching between different active ingredients within a drug class, e.g., lisinopril → losartan) is not routine generic substitution. A pharmacist may not unilaterally therapeutic-substitute; it requires a collaborative practice agreement or prescriber authorization.
4. DAW (Dispense As Written) Product-Selection Codes
Pharmacy claims transmit a DAW/product-selection code (the CMS standard, required for Medicare Part D and adopted by most payers) that documents the substitution decision:
- DAW Code Meaning
- 0 No product selection indicated—pharmacist follows state substitution law
- 1 Substitution not allowed by prescriber (brand dispensed as written)
- 2 Substitution allowed— patient requested the product dispensed
- 3 Substitution allowed— pharmacist selected the product dispensed
- 4 Substitution allowed—generic drug not available
- 5 Substitution allowed—brand over-prescribed
- 6 Substitution allowed—override
- 7 Substitution not allowed—brand drug dispensed as generic
- 8 Substitution allowed—generic not available in marketplace
- 9 Other
DAW 1 is the prescriber's lock: when "DAW" is written or checked, the pharmacist must dispense the brand or contact the prescriber to change the order. DAW 0 is the default when the prescriber gives no product-selection instruction; the pharmacist then applies state substitution rules. DAW 3 documents a pharmacist-initiated generic substitution.
Billing rule: Submitting a brand product on a generic-coded claim (or vice versa) without the correct DAW code is a common audit finding and may be treated as misrepresentation by Medicaid or a PBM.
5. MPJE Reasoning Pattern
Determine whether the prescribed and dispensed products are therapeutically equivalent (Orange Book A vs. B).
Apply state law on permissive/mandatory substitution and any NTI or DAW restriction.
Confirm the prescriber did not write DAW / "brand necessary" ; if so, dispense as written or obtain a new order.
Record the substitution, the NDC dispensed, and the correct DAW code on the claim.
Pass any allowable savings to the patient or payer where state law requires.
Bottom line: Federal law defines what is substitutable (Hatch-Waxman + Orange Book A-code); state law defines when you may or must substitute ; the DAW code documents the decision on the claim.